Wealth Enhancement Advisory Services LLC Purchases 9,480 Shares of IQVIA Holdings Inc. $IQV

Wealth Enhancement Advisory Services LLC boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 35.8% in the fourth quarter, Holdings Channel reports. The fund owned 35,960 shares of the medical research company’s stock after purchasing an additional 9,480 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in IQVIA were worth $8,674,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC increased its holdings in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new position in IQVIA in the second quarter worth approximately $514,000. Coldstream Capital Management Inc. boosted its stake in shares of IQVIA by 3.2% during the 2nd quarter. Coldstream Capital Management Inc. now owns 3,378 shares of the medical research company’s stock worth $532,000 after acquiring an additional 106 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its position in shares of IQVIA by 15.5% during the 2nd quarter. Advisors Asset Management Inc. now owns 6,729 shares of the medical research company’s stock valued at $1,060,000 after acquiring an additional 903 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQVIA stock opened at $164.08 on Friday. The company has a market capitalization of $27.84 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 1.64 and a beta of 1.39. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock’s 50-day simple moving average is $186.70 and its 200-day simple moving average is $205.21. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter last year, the company earned $3.12 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IQV has been the topic of a number of recent research reports. Citigroup decreased their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. BMO Capital Markets set a $250.00 price target on IQVIA in a research report on Friday, February 6th. Evercore reaffirmed an “outperform” rating and issued a $225.00 price objective on shares of IQVIA in a research note on Thursday, February 5th. UBS Group cut their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Finally, Morgan Stanley set a $240.00 target price on shares of IQVIA in a report on Wednesday, February 11th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $229.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.